Form 4: Revolution Medicines' General Counsel Sells Shares to Cover Tax Obligations

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,454 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• On September 16, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, sold 1,454 shares of common stock.
• The sale was executed at a price of $44.1853 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023.
• The purpose of the sale was to satisfy the reporting person's tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following the transaction, Cislini beneficially owns 45,634 shares, including 40,209 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction for tax purposes and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

Sales by company insiders are a common occurrence, especially when related to tax obligations from vesting equity. These transactions are often pre-planned under Rule 10b5-1 to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by an insider could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context of tax obligations.

Key Dates